Question

Please prepare a brief description of the reasoning for your choice of answer.

1)Based on the structure of imatinib, describe the physical and chemical properties that can account for it being orally active?  

2)What is not typically measured during a Phase I clinical trial?

a)The safety profile of the drug candidate when used in healthy subjects

b)A clinical endpoint to estimate the drug’s candidates effectiveness

c)The maximal tolerable dose of the drug candidate

d)The absorption, distribution, metabolic, and excretion properties of a drug candidate

3)Which of the following is incorrect regarding the successful completion of Phase III clinical trials?

a)Efficacy of the drug candidate in a large number of patients, usually thousands, has been confirmed

b)The drug has been tested in patients with anticipated comorbidities but not under all comorbidity circumstances

c)The full adverse drug effect profile on the population in which the drug is to be used is known

Answer 1

Imitanib is a drug used to treat cancer likechronic mylogenous leukemia, Acute lymphocytic leukemia, chronic eosinophilic leukemia etc.

Imatinib is a 2-phenyl amino pyrimidine derivative and this functions as a specific inhibitor of a number of tyrosine kinase enzymes. It usually occupies the TKactive site, leading to a decrease in activity.

In chronic myeloid leukemia,inhibits the bcr-abl tyrosine kinase which is constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality .And is effective mechanism of action as oral targeted therapy.

Hope this helps you. Thank you ?